H
Huadong Li
Researcher at Wuhan Jinyintan Hospital
Publications - 5
Citations - 7166
Huadong Li is an academic researcher from Wuhan Jinyintan Hospital. The author has contributed to research in topics: Internal medicine & Randomized controlled trial. The author has an hindex of 2, co-authored 3 publications receiving 5709 citations.
Papers
More filters
Journal ArticleDOI
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Bin Cao,Yeming Wang,Danning Wen,Wen Liu,Jingli Wang,Guohui Fan,Lianguo Ruan,Bin Song,Yanping Cai,Ming Wei,Xingwang Li,Jia'an Xia,Nanshan Chen,Jie Xiang,Ting Yu,Tao Bai,Xuelei Xie,Li Zhang,Caihong Li,Ye Yuan,Hua Chen,Huadong Li,Hanping Huang,Shengjing Tu,Fengyun Gong,Ying Liu,Yuan Wei,Chongya Dong,Fei Zhou,Xiaoying Gu,Jiuyang Xu,Zhibo Liu,Yi Zhang,Li Hui,Lianhan Shang,Ke Wang,Kunxia Li,Xia Zhou,Xuan Dong,Zhaohui Qu,Sixia Lu,Xujuan Hu,Shunan Ruan,Shanshan Luo,Jing Wu,Lu Peng,Fang Cheng,Lihong Pan,Jun Zou,Chunmin Jia,Juan Wang,Xia Liu,Shuzhen Wang,Xudong Wu,Qin Ge,Jing He,Haiyan Zhan,Fang Qiu,Li Guo,Chaolin Huang,Thomas Jaki,Frederick G. Hayden,Peter Horby,Dingyu Zhang,Chen Wang +64 more
TL;DR: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.
Journal ArticleDOI
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Yeming Wang,Yeming Wang,Dingyu Zhang,Guanhua Du,Ronghui Du,Jianping Zhao,Yang Jin,Shouzhi Fu,Ling Gao,Zhenshun Cheng,Qiaofa Lu,Yi Hu,Guangwei Luo,Ke Wang,Yang Lu,Huadong Li,Shuzhen Wang,Shunan Ruan,Chengqing Yang,Chunlin Mei,Yi Wang,Dan Ding,Feng Wu,Xin Tang,Xianzhi Ye,Yingchun Ye,Bing Liu,Jie Yang,Wen Yin,Aili Wang,Guohui Fan,Fei Zhou,Zhibo Liu,Xiaoying Gu,Jiuyang Xu,Lianhan Shang,Lianhan Shang,Yi Zhang,Lianjun Cao,Guo Tingting,Yan Wan,Hong Qin,Yushen Jiang,Thomas Jaki,Thomas Jaki,Frederick G. Hayden,Peter Horby,Bin Cao,Chen Wang +48 more
TL;DR: In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits, however, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.
Journal ArticleDOI
Risk Factors of Viral RNAaemia and Its Association With Clinical Prognosis Among Patients With Severe COVID-19.
Hui Li,Hui Li,Hui Li,Xiaoying Gu,Xiaoying Gu,Xiaoying Gu,Huadong Li,Fengyun Gong,Jiuyang Xu,Yeming Wang,Yeming Wang,Yeming Wang,Haibo Li,Haibo Li,Haibo Li,Shunan Ruan,Qingyu Yang,Bin Cao +17 more
Journal ArticleDOI
The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice
Xiaoliang Jiang,Huadong Li,Yong Liu,Linlin Bao,Lingjun Zhan,Hong Gao,Wei Deng,Jing Xue,Jiangning Liu,Xing Liu,Junli Li,Jie Wang,Shuang Wu,Mingzhe Yan,W Luo,Pedro A. Jose,Chuan Qin,Xiu-hong Yang,Dingyu Zhang,Zhi-wei Yang +19 more
TL;DR: In this paper , the authors studied COVID-19 patients with hypertension and hypertensive human(h) ACE2 transgenic mice to determine the outcome of COVID19 with or without AT1 receptor (AT1R) blocker treatment.
Journal ArticleDOI
Adenovirus-IL-10 relieves chronic rejection after mouse heart transplantation by inhibiting miR-155 and activating SOCS5
TL;DR: In this paper , the authors investigated the mechanism of IL-10 in macrophage related chronic rejection after mouse heart transplantation, and showed that IL10 negatively regulated miR-155 to activate SOCS5.